AstraZeneca picks Charles River
Relationship formalised in three-year deal
AstraZeneca has chosen Charles River Laboratories International, as its preferred strategic partner for outsourced regulated safety assessment drug metabolism and pharmacokinetics (DMPK) for three years to 2015. Earlier the same week, AstraZeneca had signed a similar agreement with Chinese CRO Pharmaron, suggesting it has more early phase work in the pipeline.
This is regarded as essentially a formalisation of an existing relationship, as AstraZeneca had already begun the process of transferring programmes to Charles River earlier this year and this should be completed by early 2013. In 2013, the incremental sales under this agreement are expected to contribute approximately 1% to Charles River’s total net sales.